221
Participants
Start Date
April 25, 2017
Primary Completion Date
April 7, 2020
Study Completion Date
April 7, 2020
Ustekinumab
All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
Hôpital Edouard Herriot, Lyon
Janssen Cilag S.A.S.
INDUSTRY